Clinical Trial

Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

Name: Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis — clinical trial record (NCT07143864)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This trial is planned to investigate the efficacy and safety of Stapokibart (an IL-4 receptor antagonist) in patients with PCA.

Trial Details

NCT Number	NCT07143864
Lead Sponsor	First Affiliated Hospital of Chongqing Medical University
Conditions	Primary Cutaneous Amyloidosis
Enrollment	40 participants
Start Date	2025-09-15
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-27